NCT05256225 2026-04-16
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
Phase 3 Recruiting
National Cancer Institute (NCI)
American Society of Clinical Oncology
QuantumLeap Healthcare Collaborative
Deraya University
DualityBio Inc.